Anterran Pharmaceuticals and Health Organisation

The Anterran Pharmaceuticals and Health Organisation (APHO) is an international organisation dedicated to public health and pharmaceutical research, founded in 2003, it is headquartered in Masazi, Baileneu Ma. The organisation consists of three branches: APHO:EPI; specialising in epidemiology on a global and local scale, APHO:RND; dedicated to research and development of new pharmaceutical drugs and medical treatments, APHO:PUB created for public health projects such as vaccinations and disaster relief. Advocating for universal healthcare, human longevity, sustainable development and health co-ordination schemes, APHO often acts alongside existing charities and state authorities in its efforts, in order to efficiently and effectively deal with health risks. Notable for its role in the near eradication of Marasmavirus, Jollo- and Neffeje- strains and  in Baileneu Ma, co-ordinating its vaccination and quarantine efforts with the NHS.

APHO:RND
APHO:RND identified 5 main projects at a conference in 2014, consisting of cancer research, antibiotic resistant bacteria eradication, genetic disease research, tropical disease management and obesity reduction. Cancer research has been the largest sector of research in recent years from APHO, mainly focusing on cancer treatment and diagnosis, with new drugs such as 'Yulixane' and 'Chromevirane' being trialed in Baileneu Ma, with release and distribution of the drugs intended for 2022. Yulixane has shown particular usefulness in the apoptosis and inhibition of tumours, as well as helping to ease nausea, swelling and appetite loss from chemotherapy and radiotherapy. Chromevirane has also shown potential in reducing the seizures created by brain tumours and epilepsy, representing important milestones in the treatment of cancer. Vincristine, Mitomycin C, Demecolcine and Floxuridine, amongst many other antineoplastic/chemotherapeutic agents, are currently mass-produced across Anterra, although a new generation of cancer treatment pharmaceuticals are being developed, according to a report published in 2019.

Synthetic DNA research (xenobiology), spearheaded by ECOSEAS donors has also led to the development of synthetic enzymes, known as X-enzymes, showing new promise in the treatment of genetic diseases such as cystic fibrosis, as well as cancer tumour apoptosis, inhibition and diagnosis. The creation of XNA micro-organisms has also spurred on new research in the applications of XNA vaccines, where weakened pathogens can be developed and mass produced, reducing the production costs and time required to develop vaccines. X-enzymes are also thought to be more effective than existing enzymes and antibodies administered in hospitals, as it takes longer for these X-enzymes to be metabolised as they are foreign to the human body. Stem-cell research has also been a major focus of APHO:RND, being trialed for treatment in multiple sclerosis, Alzheimers and other neurodegenerative diseases, as well as restoring vision and hearing in a medical trial conducted in Baileneu Ma. Stem cell research and xenobiology have been controversial in many APHO member states, due to potential ethical concerns in the use of foetuses and 'playing God'.